Bausch + Lomb (BLCO) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic transformation, vision, and innovation

• Emphasis on cultural shifts, leadership renewal, and a return to an innovation-driven mindset, focusing on meaningful products and platforms that address real patient needs.

• Technology modernization across R&D, manufacturing, and digital tools has led to increased patent filings and improved operational efficiency, with 59 new patent applications in 2025, up from 42 in 2013.

• Company-wide innovation culture now drives product design, digital capabilities, and customer engagement, supporting durable growth and margin expansion.

• Strategy emphasizes above-market revenue growth, margin expansion, and robust cash flow generation, with all business segments contributing to a targeted 5–7% constant currency revenue CAGR from 2025–2028.

• Focus on disruptive innovation and elevating standard of care across all business lines.

Pipeline and product launches

• Multiple high-impact launches planned: AREDS 3 for AMD, Elios MIGS for glaucoma, new preservative-free drops, premium eye care products, and a bioactive contact lens (Project Halo) expected in 2028.

• Pipeline includes myopia control lens, neurosensory agent for OSP, dual-action dry eye drops, and a glaucoma asset with neuroprotective benefits, with peak sales potential ranging from $200M to $3.9B.

• Major launches planned between 2026–2031, including glaucoma therapy, AMD/GA game changers, and next-gen surgical devices.

• Projected total peak sales from pipeline products estimated at ~$7B, with launches staggered by product.

• Ongoing clinical studies and regulatory submissions support robust innovation pipeline.

Market positioning and business performance

• Maintains #1 global OTC eye health position, with strong momentum in consumer and contact lens segments, and brands like PreserVision, Ocuvite, and Lumify Luxe driving growth.

• Contact lens segment outperforms market, with new launches in 60+ countries and premium products targeting multifocal, astigmatism, and myopia control.

• Expanding in premium surgical categories with new IOLs, lasers, and cataract/retina combo devices, targeting peak sales up to $450M per product.

• Pharma segment driven by MIEBO and Xiidra, with combination therapies and new indications supporting future growth.

• All business segments forecast 5–7% CAGR through 2028.